Abstract
Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have